NBTXR3, hafnium oxide nanoparticles in the treatment of liver cancer: a phase I/II trial

ASCO, Chicago, IL · 2018, Chajon E. et al.


Chajon E.1, Pracht M.1, de Baere T.2, Nguyen F.2, Bronowicki J.P.3, Vendrely V.4, Baumann A.S.5, Croisé-Laurent V.3, Rio E.6, Rolland Y.1, Le Sourd S.1

1 – Radiation Oncology, Centre Eugene – Marquis, Rennes, France
2 – Radiation oncology, Institut Gustave Roussy, Villejuif, France
3 – Hepatology and Gastroenterology, Hôpital de Brabois, Vandoeuvre Les Nancy, France
4 – Radiotherapy, Groupe Hospitalier Sud – Hôpital Haut-Lévêque, Pessac, France
5 – Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, France
6 – Radiotherapy, Institut de cancérologie de l’Ouest, Nantes, France


Hepatocellular carcinoma (HCC) is the most widespread primary liver cancer. Liver metastasis (mets) are even more common with a wide range of malignancies. Management of both liver affections is a challenging task regarding toxicity toward liver functions. In response, NBTXR3, innovative injectable hafnium oxide nanoparticles activated by radiotherapy, was developed to increase the local deposit of energy within the tumor cells without negatively affecting the liver. It is currently evaluated in a phase I/II clinical trial to introduce the use of NBTXR3 with stereotactic body radiation therapy (SBRT) in patients with HCC or liver mets [NCT02721056].

Overall, current results observed a safe and well tolerated profile for NBTXR3 indicating an encouraging perspective in patients highly vulnerable to liver complications. This multidisciplinary study brought together the successful complex cooperation of several centers and of different medical disciplines to treat two types of liver affections with an innovative approach.

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.